The new drug development in MBC focuses primarily on early-mid stage clinical trials of projects that MBC owns sole or partial commercialization rights. The core competency of MBC team is the buildup of an in-house clinical trial CRO team which is capable of conducting a full range of clinical trials under US FDA or EMEA regulations, including protocol design, site selecting, study management and monitoring, study report completion, inspection assistance and submission of NDA. 
Staff members in the Division of New Drug Development have substantial background and experience in medicine, and in particular in oncology and liver diseases. The team translates the developing targets from science to clinical applications through efficient conduction of clinical trials, by integrating expertise of regional medical professionals together in a cost-effective scheme, to add value to the project with proven quality.

MBC had co-developed PI-88 with Progen Pharmaceutical Limited since 2001. Through this Strategic Alliance, MBC initiated a multicentric randomized Phase II trial in Taiwan targeting resectable/operable hepatocellular carcinoma of the liver as the indication. This pioneer clinical design was awarded by demonstrating promising Phase II data on the reduction of post-resection liver cancer recurrence rate from 50% to 37% (control vs study group). PI-88 also showed efficacy in delaying the onset of recurrence (time to recurrence) from 27 weeks to 48 weeks. These results received positive feedbacks from the FDA, and hence prompted the decision of Progen Pharma to buy-back the rights of MBC in this project and to launch a Phase III global trial on its own. This is the first track-record of MBC in clinical development. Subsequent to the experience, MBC has entered into another strategic alliance and licensing agreement with Oncolys BioPharma of Japan to develop and potentially commercialize Telomelysin (OBP-301), a novel oncolytic virotherapy for cancers. OBP-301 is in FDA's Phase I stage at the present and is anticipated to move into Phase II in 2009. Targeted indications are liver cancer, head & neck cancer, esophageal cancer, and/or prostate cancer. Under this agreement, MBC and Oncolys will jointly complete phase-II trials, and seek for out-licensing opportunities afterward. Inherited from prior PI-88 alliance, this strategic alliance aims to increase Telomelysin value, where both companies, upon successful completion of the phase-II will share future potential revenues at pre-set Revenue-Sharing-Ratio.
Based on the successful experience and track record on PI-88, MBC has continuously negotiated with biotech companies, pharmaceuticals, and research institutions for development collaborations, focusing on the core competences of developing new treatments for liver diseases and cancer, and liver cancer in particular.

The pipeline of new drug development involves several clinical and pre-clinical projects for liver cancer at different stages of development. Eventually, MBC aims at offering total solutions for liver cancer of different clinical severity (stages) in the next 10 years by providing a series of innovative therapies/technologies, and becoming a “Liver Cancer Specialty Pharma” in 10 years and beyond.